Rothschild Redb Upgrades Stryker (NYSE:SYK) to Hold

Key Points

• Stryker's stock has been upgraded to a "hold" rating by Rothschild Redburn, following similar upgrades to a "buy" rating from several other analysts.
• The company's most recent quarterly earnings report showed an EPS of $3.13, surpassing estimates, with revenues of $6.02 billion, reflecting an 11.1% year-over-year increase.
• Stryker's current average rating stands at "Moderate Buy" with a consensus price target of $430.33, as 14 analysts have rated it a buy.

Stryker (NYSE:SYK - Get Free Report) was upgraded by stock analysts at Rothschild Redb to a "hold" rating in a report released on Thursday,Zacks.com reports.

A number of other research analysts also recently issued reports on SYK. Truist Financial set a $415.00 price target on Stryker and gave the company a "hold" rating in a report on Monday, August 4th. Redburn Partners set a $420.00 price target on shares of Stryker in a report on Thursday. Rothschild & Co Redburn assumed coverage on shares of Stryker in a research report on Thursday. They set a "neutral" rating and a $420.00 price objective on the stock. Citigroup restated a "buy" rating and issued a $455.00 target price (up previously from $443.00) on shares of Stryker in a report on Thursday, May 22nd. Finally, Wall Street Zen upgraded shares of Stryker from a "hold" rating to a "buy" rating in a report on Friday, July 18th. Fourteen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company's stock. According to MarketBeat.com, Stryker currently has an average rating of "Moderate Buy" and a consensus target price of $430.33.

Stryker Stock Up 0.5%

NYSE:SYK traded up $1.87 during trading hours on Thursday, reaching $378.70. 2,095,205 shares of the company traded hands, compared to its average volume of 1,395,384. The company has a current ratio of 1.78, a quick ratio of 1.06 and a debt-to-equity ratio of 0.70. The business's 50-day moving average price is $387.52 and its two-hundred day moving average price is $379.05. Stryker has a 1 year low of $329.16 and a 1 year high of $406.19. The stock has a market capitalization of $144.78 billion, a P/E ratio of 50.16, a P/E/G ratio of 2.71 and a beta of 0.93.

Stryker (NYSE:SYK - Get Free Report) last released its earnings results on Thursday, July 31st. The medical technology company reported $3.13 EPS for the quarter, topping the consensus estimate of $3.07 by $0.06. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The business had revenue of $6.02 billion for the quarter, compared to the consensus estimate of $5.92 billion. During the same period in the previous year, the company posted $2.81 earnings per share. The company's revenue for the quarter was up 11.1% compared to the same quarter last year. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. Analysts predict that Stryker will post 13.47 earnings per share for the current year.

Insider Activity at Stryker

In other Stryker news, insider Viju Menon sold 500 shares of the firm's stock in a transaction dated Monday, August 25th. The shares were sold at an average price of $390.61, for a total value of $195,305.00. Following the completion of the sale, the insider owned 12,511 shares of the company's stock, valued at $4,886,921.71. This trade represents a 3.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Ronda E. Stryker sold 200,000 shares of the stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total value of $75,290,000.00. Following the completion of the transaction, the director directly owned 3,222,108 shares in the company, valued at approximately $1,212,962,556.60. This trade represents a 5.84% decrease in their position. The disclosure for this sale can be found here. 5.20% of the stock is owned by company insiders.

Institutional Trading of Stryker

Institutional investors have recently made changes to their positions in the business. Mid American Wealth Advisory Group Inc. purchased a new stake in Stryker during the second quarter worth $26,000. Capital A Wealth Management LLC purchased a new stake in Stryker during the fourth quarter worth $26,000. Elevation Point Wealth Partners LLC purchased a new stake in Stryker during the second quarter worth $28,000. Sachetta LLC boosted its holdings in Stryker by 58.7% during the second quarter. Sachetta LLC now owns 73 shares of the medical technology company's stock worth $29,000 after buying an additional 27 shares in the last quarter. Finally, Kilter Group LLC acquired a new stake in shares of Stryker during the 2nd quarter valued at about $29,000. Institutional investors and hedge funds own 77.09% of the company's stock.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.